New study tracks Darolutamide's Real-World impact on advanced prostate cancer

NCT ID NCT07344779

Ongoing Disease control Sponsor: Bayer Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This observational study follows about 1,600 men with metastatic hormone-sensitive prostate cancer who are taking darolutamide plus hormone therapy, with or without chemotherapy. Researchers will track how many men have undetectable PSA levels after one year, as well as overall survival and side effects. The goal is to see how well this treatment works in everyday medical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC HORMONE-SENSITIVE PROSTATE CANCER

Contacts and locations

Locations

Many Locations

Multiple Locations, Belgium
Many Locations

Multiple Locations, Finland
Many Locations

Multiple Locations, France
Many Locations

Multiple Locations, Germany
Many Locations

Multiple Locations, Greece
Many Locations

Multiple Locations, Israel
Many Locations

Multiple Locations, Italy
Many Locations

Multiple Locations, Lithuania
Many Locations

Multiple Locations, Norway
Many Locations

Multiple Locations, Poland
Many Locations

Multiple Locations, Portugal
Many Locations

Multiple Locations, Saudi Arabia
Many Locations

Multiple Locations, Spain
Many Locations

Multiple Locations, Sweden
Many Locations

Multiple Locations, Switzerland
Many Locations

Multiple Locations, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.